Market Research Reports and Industry Reports

World Continuous Glucose Monitoring Systems - Market Opportunities and Forecasts, 2014 - 2021

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Continuous Glucose Monitoring (CGM) is one of the latest technological advancements in the field of diabetes management. CGM systems are a type of glucose monitoring devices that function by inserting a biosensor through transcutaneous or subcutaneous route. The embedded sensor measures the glucose levels in the interstitial fluid or in the blood and results are transmitted via a transmitter to a receiver/monitor that displays the results. CGM systems have emerged as an integral part of diabetes management owing to its several advantages over other glucose monitoring devices. Unlike conventional glucose monitors, these systems enable periodic monitoring of glucose levels, which is crucial to avoid any diabetic complications. In addition, CGMS technology has laid a roadmap to the most awaited, high-tech, closed-loop ‘artificial/bionic pancreas’. Therefore, developing novel and technologically advanced CGMS is the prime focus of several glucose monitoring device manufacturing companies. CGMS offer a wide range of applications across all age-cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs and home healthcare) and geographies. Thus, CGMS market shows lucrative opportunity for both CGMS manufacturers and insulin pump manufacturers.

The global CGMS market is forecast to reach $2.9 billion by 2021 registering a CAGR of 31.4% over the forecast period. The pipeline of high-tech CGMS devices, such as smartphone-connected CGMS, wearable and smartphone-connected CGMS, non-invasive CGMS and ‘smart’ diabetes management solution (also called artificial/bionic pancreas), would result in larger adoption of CGMS among endocrinologists and patients.

The market is categorized based on components, customer segments, end-user demographics and geographic regions. The CGMS components market includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. The segment for sensors occupies a dominant share in the CGMS market primarily due to the recurring sales of CGMS, short scrap life and bulk purchases. CGMS are deployed primarily by the diagnostic centers/clinics. Moreover, increasing usage of CGMS across the hospital ICUs and in-home healthcare settings has been observed. The CGMS devices market by age demographics is categorized as juveniles, Gen X and geriatrics.

Detailed geographical analysis and segmentation is provided at country-level per-region—North America (U.S., Canada and Mexico), Europe (U.K., France, Germany and others), Asia-Pacific (India, China and Australia) and LAMEA (Gulf Cooperation Council). Key market players include Medtronic plc, Dexcom, Inc., Abbott Diabetes Care, Animas Corporation, including others. The major strategies adopted by the market players across geographies are collaborations, product launches and approvals. Collaborations in the regions focus on innovation, distribution and commercialization of the devices.

KEY BENEFITS

In-depth and country-level analysis within all the geographic regions would provide a clear understanding of current and future trends in the CGMS market

Comprehensive analysis of factors that drive and restrict the growth of the CGMS market is provided

The report covers detailed quantitative analysis of the current market and estimations through 2014–2021, which would enable the stakeholders to capitalize on prevailing market opportunities

A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation

An in-depth analysis of current research and clinical developments within CGMS market is provided with key market dynamic factors that help in understanding the behavior of market

Key market players within the CGMS market are profiled in the report and their strategies are analyzed thoroughly, which help in understanding the competitive outlook of the global CGMS market

KEY MARKET SEGMENTS

The CGMS market is segmented based on components, customer segments, end-user demographics and geography (country-level).

Global CGMS Market - by Components

Sensors

Transmitters & Receivers

Integrated insulin pumps

Global CGMS Market - by Customer Segments

Diagnostics/Clinic

ICUs

Home Healthcare

Global CGMS Market - by End-user Demographics

Juveniles

Gen X

Geriatrics/undiagnosed

Global CGMS Market - by Geography

North America

United States

Canada

Mexico

Europe

United Kingdom

Germany

France

Others

Asia-Pacific

China

India

Australia

Others

LAMEA

Gulf Cooperation Council (GCC)

Others

Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models



$0(SU)
Chapter: 2 EXECUTIVE SUMMARY


$506(SU)
Chapter: 3 MARKET OVERVIEW
3.1 Market definition
3.2 Need for glucose monitoring systems

3.2.1 Diabetes ââ¬Å a pandemic

3.2.1.1 Type 1 diabetes
3.2.1.2 Type-2 diabetes
3.2.1.3 Pre-diabetes and Gestational Diabetes Mellitus (GDM)
3.2.1.4 Gestational Diabetes Mellitus (GDM)
3.2.1.5 Secondary diabetes

3.2.2 Global healthcare expenditure on diabetes

3.3 Emerging technologies in CGMS

3.3.1 Smartphone-connected CGMS
3.3.2 Wearable and smartphone-connected CGMS
3.3.3 Non-invasive CGMS
3.3.4 Invasive CGMS in the R&D pipeline
3.3.5 Smart â⢠diabetes management solution ââ¬Å Bionic Pancreas

3.4 CGMS -Â Prime end user segments

3.4.1 CGMS ââ¬Å crucial need in Intensive Care Units (ICUs)

3.4.1.1 ÃÅStress Hyperglycemia â⢠ââ¬Å common occurrence in ICUs
3.4.1.2 Non-standardization and erroneous glycemic control across ICUs

3.4.2 Benefits and factors driving adoption of CGMS in ICUs

3.4.2.1 CGMS aid in Tight Glycemic Control in ICUs
3.4.2.2 Cost benefits from usage of CGMS
3.4.2.3 POC Glucometers less effective in ICUs - as compared to CGMS
3.4.2.4 CGMS ââ¬Å most preferred by ICU staff

3.5 Key findings

3.5.1 Top impacting factors
3.5.2 Top investment pockets

3.5.2.1 CGMS market ââ¬ÅBy End User Segments
3.5.2.2 CGMS market ââ¬Å by geography

3.5.3 Top winning strategies

3.6 Value chain analysis
3.7 Market share analysis, 2014
3.8 Government regulations
3.9 Reimbursement scenario
3.10 Drivers

3.10.1 Rise in incidence of diabetes globally
3.10.2 Inherent benefits of CGMS over POC glucometers ââ¬Å drive market growth
3.10.3 Increase in awareness in developing and underdeveloped economies
3.10.4 Focus on developing OTC/POC CGMS catering to new end user segment - future growth driver
3.10.5 FDA, U.S. approval of Bionic Pancreas ââ¬Å future growth driver

3.11 Restraints

3.11.1 Stringent regulatory requirements
3.11.2 Inadequate reimbursements ââ¬a barrier in CGMS adoption
3.11.3 Accuracy and cost ââ¬a hindrance in continuing use of CGMS

3.12 Opportunities

3.12.1 Higher adoption rate of CGMS in ICUs
3.12.2 OTC/POC CGMS - expanded product applications/usage
3.12.3 ÃÅUndiagnosed â⢠patient population

3.13 Winning strategies for MNCs for entering emerging markets

3.13.1 Gaining CE approvals for a speedier entry into Asia--Pacific and LAMEA markets
3.13.2 Forming distribution alliances to enhance geographical reach
3.13.3 Raising end-user awareness and competitive product pricing



$822(SU)
Chapter: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS
4.1 Stand-alone and Integrated CGM systems

4.1.1 Market size and forecast

4.2 Sensors

4.2.1 Key market trends

4.2.1.1 Non-invasive glucose sensors
4.2.1.2 Subcutaneous sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional technology ââ¬holter-yype retrospective sensors
4.2.1.4 Advanced technology ââ¬Real-Time sensors

4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Transmitters &Â Receivers

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 Integrated Insulin pumps

4.4.1 Overview
4.4.2 Key market trends
4.4.3 Key growth factors and opportunities
4.4.4 Market size and forecast



$1391(SU)
Chapter: 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT
5.1 Market size and forecast
5.2 Diagnostic centers/clinics

5.2.1 Market size and forecast

5.3 ICUs

5.3.1 Market size and forecast

5.4 Home healthcare

5.4.1 Market size and forecast



$1138(SU)
Chapter: 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET Â BY AGE DEMOGRAPHICS
6.1 Juveniles
6.2 Gen X
6.3 Geriatrics / undiagnosed



$569(SU)
Chapter: 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY
7.1 North America

7.1.1 Market size and forecast
7.1.2 U.S.
7.1.3 Canada
7.1.4 Mexico

7.2 Europe

7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.4 France

7.2.4.1 Key market trends
7.2.4.2 Key growth factors and opportunities

7.2.5 Germany

7.2.5.1 Key market trends
7.2.5.2 Key growth factors and opportunities

7.2.6 U.K.

7.2.6.1 Key market trends
7.2.6.2 Key growth factors and opportunities

7.2.7 Other European countries

7.3 Asia-Pacific

7.3.1 Market size and forecast
7.3.2 India

7.3.2.1 Key market trends

7.3.3 Australia

7.3.3.1 Key market trends

7.3.4 China

7.3.4.1 Key market trends

7.3.5 Other APAC countries

7.4 LAMEA

7.4.1 Overview
7.4.2 Market size and forecast
7.4.3 Gulf Cooperation Council (GCC)

7.4.3.1 Key market trends



$1264(SU)
Chapter: 8 COMPANY PROFILES
8.1 Medtronic Plc.

8.1.1 Company overview
8.1.2 Business performance
8.1.3 Strategic moves and developments

8.1.3.1 Principal strategies: product launch
8.1.3.2 Secondary strategies: approval
8.1.3.3 Other strategies: strategic alliance and collaboration

8.1.4 SWOT analysis of Medtronic Plc

8.2 Dexcom Inc.

8.2.1 Company overview
8.2.2 Business performance
8.2.3 Strategic moves and developments

8.2.3.1 Principal strategies: agreement/partnership
8.2.3.2 Secondary strategies: approval
8.2.3.3 Other strategies: acquisition

8.2.4 SWOT analysis of Dexcom

8.3 Abbott Diabetic Care (Abbott Laboratories)

8.3.1 Company overview
8.3.2 Business performance
8.3.3 Strategic moves and developments
8.3.4 SWOT analysis of Abbott diabetic care

8.4 Animas Corporation

8.4.1 Company overview
8.4.2 Strategic moves and developments
8.4.3 SWOT analysis of Animas Corporation

8.5 Echo Therapeutics

8.5.1 Company Overview
8.5.2 Strategic moves and development
8.5.3 SWOT Analysis of Echo Therapeutics

8.6 Insulet Corporation

8.6.1 Company overview
8.6.2 Strategic moves and developments
8.6.3 SWOT analysis of INSULET Corporation

8.7 Glysens Inc.

8.7.1 Company overview
8.7.2 Strategic moves and developments
8.7.3 SWOT Analysis of Glysens Inc.

8.8 Senseonics, Inc.

8.8.1 Company overview
8.8.2 Strategic moves and development
8.8.3 SWOT analysis of Senseonics, Inc.


List Of Tables

TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2014)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2013)
TABLE 3 GLOBAL CGM MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 4 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2014 “2021 ($MILLION)
TABLE 5 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 6 GLOBAL CGM INTEGRATED INSULIN PUMPS MARKET BY GEOGRAPHY, 2014 “2021 ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY END USER SEGMENT, 2014-2021 ($MILLION)
TABLE 8 GLOBAL CGM DIAGNOSTIC CENTRES/CLINICS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 9 GLOBAL CGM ICUS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 10 GLOBAL CGM HOME HEALTHCARE MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 11 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 12 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2014 AND 2021
TABLE 13 GLOBAL CGMS BY GEOGRAPHY, 2014-2021 ($MILLION)
TABLE 14 NORTH AMERICA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 15 NORTH AMERICA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 18 EUROPE CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 19 TOP 10 COUNTRIES WITH DIABETES INCIDENCE 2013 AND 2035
TABLE 20 PREVALENCE ESTIMATES OF DIABETES, 2013 AND 2035
TABLE 21 APAC CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 22 APAC CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 23 MEDICAL DEVICES USED IN AUSTRALIA
TABLE 24 LAMEA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
TABLE 25 LAMEA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
TABLE 26 MEDTRONIC BUSINESS SNAPSHOT
TABLE 27 MEDTRONIC REVENUE BY BUSINESS UNITS (2014)
TABLE 28 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 29 ABBOTT DIABETIC CAREBUSINESS SNAPSHOT
TABLE 30 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 31 ECHO THERAPEUTICS COMPANY SNAPSHOT
TABLE 32 INSULET CORPORATION BUSINESS SNAPSHOT
TABLE 33 GLYSENS INC. BUSINESS SNAPSHOT
TABLE 34 SENSEONICS, INC. SNAPSHOT


List Of Figures

FIG. 1 PREVALENCE OF TYPE 1 DIABETES (AGED FIG. 2 GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
FIG. 3 PREDISPOSITION AND RISK FACTORS “ SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
FIG. 4 GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20 “79 YEARS)
FIG. 5 GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIG. 6 OCCURENCE OF HYPERGLYCEMIA IN ICUS
FIG. 7 TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
FIG. 8 TOP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
FIG. 9 TOP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
FIG. 10 TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
FIG. 11 TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010 “2014 (SEPTEMBER)
FIG. 13 MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
FIG. 14 GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
FIG. 15 PATIENT POPULATION UNDIAGNOSED FOR DIABETES , 2013 (MILLION)
FIG. 16 GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
FIG. 17 CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
FIG. 18 CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
FIG. 19 MEDTRONIC REVENUE BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS OF MEDTRONIC PLC
FIG. 21 SWOT ANALYSIS OF DEXCOM INC.
FIG. 22 REVENUE BY BUSINESS SEGMENT (2014)
FIG. 23 SWOT ANALYSIS OF ABBOTT DIABETIC CARE
FIG. 24 SWOT ANALYSIS OF ANIMAS CORPORATION
FIG. 25 SWOT ANALYSIS OF ECHO THERAPEUTICS
FIG. 26 SWOT ANALYSIS OF INSULET CORPORATION
FIG. 27 SWOT ANALASIS OF GLYSEN INCORPORATED
FIG. 28 SWOT ANALYSIS OF SENSEONICS, INC.


W.O.M. World Of Medicine GmbH Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

W.O.M. World Of Medicine GmbH Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

Villa World Limited Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Villa World Limited Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT

USD 200View Report

US WorldMeds, LLC Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

US WorldMeds, LLC Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT profile,

USD 200View Report

Global Continuous Glucose Monitoring Market Research Report 2016

2016 Global Continuous Glucose Monitoring Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Continuous Glucose Monitoring industry, focusing on the

USD 2850View Report

Global Continuous Glucose Monitoring Systems Sales Market Report 2021

This report studies sales (consumption) of Continuous Glucose Monitoring Systems in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these

USD 4000View Report

United States Continuous Glucose Monitoring Systems Sales Market Report 2021

This report studies sales (consumption) of Continuous Glucose Monitoring Systems in USA market, focuses on the top players, with sales, price, revenue and market share for each player, covering

USD 3800View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF    $ 4515
  • Site Licence    $ 7350
  • Global Licence    $ 10680
  • Hard copy    $ 5325
  • CD    $ 5325
$ 4515

Reports Details

Published Date : Jun 2015
No. of Pages :118
Country :Global
Category :Telecommunications
Publisher :Allied Market Research
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment